Quantitative assessment of barriers to the clinical development and adoption of cellular therapies: A pilot study

Benjamin M Davies, Sarah Rikabi, Anna French, Rafael Pinedo-Villanueva, Mark E Morrey, Karolina Wartolowska, Andrew Judge, Robert E MacLaren, Anthony Mathur, David J Williams, Ivan Wall, Martin Birchall, Brock Reeve, Anthony Atala, Richard W Barker, Zhanfeng Cui, Dominic Furniss, Kim Bure, Evan Y Snyder, Jeffrey M KarpAndrew Price, Andrew Carr, David A Brindley

Research output: Contribution to journalReview articlepeer-review


There has been a large increase in basic science activity in cell therapy and a growing portfolio of cell therapy trials. However, the number of industry products available for widespread clinical use does not match this magnitude of activity. We hypothesize that the paucity of engagement with the clinical community is a key contributor to the lack of commercially successful cell therapy products. To investigate this, we launched a pilot study to survey clinicians from five specialities and to determine what they believe to be the most significant barriers to cellular therapy clinical development and adoption. Our study shows that the main concerns among this group are cost-effectiveness, efficacy, reimbursement, and regulation. Addressing these concerns can best be achieved by ensuring that future clinical trials are conducted to adequately answer the questions of both regulators and the broader clinical community.

Original languageEnglish
JournalJournal of Tissue Engineering
Publication statusPublished - 22 Sept 2014

Bibliographical note

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (http://www.uk.sagepub.com/aboutus/openaccess.htm).


Dive into the research topics of 'Quantitative assessment of barriers to the clinical development and adoption of cellular therapies: A pilot study'. Together they form a unique fingerprint.

Cite this